ESG416

ESG416 is an investigational antibody-drug conjugate (ADC) being developed by Shanghai Escugen Biotechnology. As part of the company's oncology-focused pipeline, ESG416 is designed to utilize a monoclonal antibody to deliver a cytotoxic payload directly to cells expressing a specific, though currently undisclosed, target antigen. The drug is in the early stages of development, and details regarding its molecular target, cytotoxic payload, and linker technology remain confidential. While no specific clinical indications have been publicly announced, the ADC modality is primarily employed in the treatment of solid tumors and hematological malignancies.